Vaccines do not exist for most STDs, and because vaccine development and implementation is costly and time-consuming, officials of the World Health Organization and the National Institutes of Health have recognized that on practical approach to control and prevention of STDs is development of topical microbicides which would be affordable, stable at ambient temperature and could be used discreetly by women. Vaginal microbicides are products for vaginal administration that can be used to prevent human immunodeficiency virus (HIV) infection and/or infections by other STDs. During the three years since this Program Project was initiated, great success has been achieved in establishing tubular, vaginal, human epithelial xenografts and susceptibility of these grafts to representative STDs [HPV and herpes simplex virus type 2 (HSV-2)] has been demonstrated. Uninfected grafts recapitulate the histological and cytochemical features of normal human vagina while infected grafts produce a profile of pathologic features and virus macromolecular synthesis identical to those in patient lesions. Xenografts have also been successfully used to demonstrate microbicidal prevention of HPV infection (by microbicides from the alkyl sulfate chemical family and by the microbicide C31G) as well as HSV-2 infection (by C1G). In the next phase of the grant, we will expand use of this model.
Our Specific Aims will be to: (1) Continue characterization of human xenografts at the tissue and cellular level by: (a) Optimizing growth parameters for the grafts, including comparison of growth in nude mice, severe combined immunodeficient (SCID) mice, and SCID mice reconstituted with human lymphoreticular cells; (b) Characterizing the profile of xenografts in a progesterone-dominant (as opposed to an estrogen-dominant) state; (b) Determining the repertoire of non-epithelial cells, specifically lymphoreticular cells, in the xenografts: (2) Complete the characterizing of the toxicity and efficacy of alkyl sulfate microbicides in the human vaginal xenograft system: (3) Determine the minimal inhibitory concentrations of non-formulated and formulated alkyl sulfates in inactivating or interdicting establishing grafts from human, fetal anal epithelium, in which efficacy of microbicides and infections of this target tissue might be studied.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
5P01AI037829-07
Application #
6500317
Study Section
Special Emphasis Panel (ZAI1)
Project Start
2001-09-01
Project End
2002-08-31
Budget Start
Budget End
Support Year
7
Fiscal Year
2001
Total Cost
Indirect Cost
Name
Pennsylvania State University
Department
Type
DUNS #
129348186
City
Hershey
State
PA
Country
United States
Zip Code
17033
Passic, Shendra R; Ferguson, Mary Lee; Catalone, Bradley J et al. (2010) Structure-activity relationships of polybiguanides with activity against human immunodeficiency virus type 1. Biomed Pharmacother 64:723-32
Pavlovic, Jelena; Floros, Joanna; Phelps, David S et al. (2008) Differentiation of xenografted human fetal lung parenchyma. Early Hum Dev 84:181-93
Beer, Brigitte E; Doncel, Gustavo F; Krebs, Fred C et al. (2006) In vitro preclinical testing of nonoxynol-9 as potential anti-human immunodeficiency virus microbicide: a retrospective analysis of results from five laboratories. Antimicrob Agents Chemother 50:713-23
Fang, L; Meyers, C; Budgeon, L R et al. (2006) Induction of productive human papillomavirus type 11 life cycle in epithelial cells grown in organotypic raft cultures. Virology 347:28-35
Hartmann, Sandra Urdaneta; Wigdahl, Brian; Neely, Elizabeth B et al. (2006) Biochemical analysis of human milk treated with sodium dodecyl sulfate, an alkyl sulfate microbicide that inactivates human immunodeficiency virus type 1. J Hum Lact 22:61-74
Deka, Srilekha; Vanover, Jennifer; Dessus-Babus, Sophie et al. (2006) Chlamydia trachomatis enters a viable but non-cultivable (persistent) state within herpes simplex virus type 2 (HSV-2) co-infected host cells. Cell Microbiol 8:149-62
Hartmann, Sandra Urdaneta; Berlin, Cheston M; Howett, Mary K (2006) Alternative modified infant-feeding practices to prevent postnatal transmission of human immunodeficiency virus type 1 through breast milk: past, present, and future. J Hum Lact 22:75-88; quiz 89-93
Fang, L; Budgeon, L R; Doorbar, J et al. (2006) The human papillomavirus type 11 E1/E4 protein is not essential for viral genome amplification. Virology 351:271-9
Urdaneta, Sandra; Wigdahl, Brian; Neely, Elizabeth B et al. (2005) Inactivation of HIV-1 in breast milk by treatment with the alkyl sulfate microbicide sodium dodecyl sulfate (SDS). Retrovirology 2:28
Krebs, Fred C; Miller, Shendra R; Ferguson, Mary Lee et al. (2005) Polybiguanides, particularly polyethylene hexamethylene biguanide, have activity against human immunodeficiency virus type 1. Biomed Pharmacother 59:438-45

Showing the most recent 10 out of 35 publications